Prescribing and Monitoring Schedule II Controlled Substances

Clinical Guidelines for Prescribing Schedule II Medications

The American Academy of Child and Adolescent Psychiatry recommends monthly follow-up appointments until symptoms stabilize on a consistent dose, which naturally aligns with 30-day prescription intervals during the titration phase 2
The American Academy of Pediatrics suggests that adolescents and adults require particularly close monitoring for signs of diversion (using medication for non-medical purposes or sharing/selling it), which is a special concern with Schedule II stimulants 1, 5
During maintenance treatment, patients should be monitored at least monthly initially, with systematic assessment of blood pressure, pulse, weight, sleep quality, appetite changes, and signs of medication misuse or diversion, as recommended by the American Academy of Child and Adolescent Psychiatry 2

Insurance coverage often restricts Schedule II medications to 30-day supplies regardless of prescription duration, requiring prior authorization for extended supplies, as noted in Pediatrics 1

Patients with comorbid substance use disorders should receive shorter prescription intervals (potentially weekly) with close monitoring for signs of misuse, as recommended by the American Academy of Pediatrics 1, 5
New patients or those with unstable symptoms require more frequent clinical contact, making monthly prescriptions appropriate for ongoing assessment, according to the American Academy of Child and Adolescent Psychiatry 2